Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127451461 | 12745146 | 1 | I | 20130904 | 20131004 | 20160915 | 20160915 | EXP | US-ROCHE-1285338 | ROCHE | 76.00 | YR | F | Y | 61.40000 | KG | 20160915 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127451461 | 12745146 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Unknown | LAST DOSE ON 06/SEP/2013 WAS 609 MG | 125085 | ||||||||||
| 127451461 | 12745146 | 2 | SS | VELIPARIB | VELIPARIB | 1 | Oral | ON DAYS 1-28, LAST DOSE ON 06/SEP/2013 WAS 1520 MG | U | 0 | 2080 | MG | BID | ||||||
| 127451461 | 12745146 | 3 | SS | CARBOPLATIN. | CARBOPLATIN | 1 | Intravenous (not otherwise specified) | AUC5, OVER 30 MINUTES ON DAY 1, LAST DOSE ON 23/AUG/2013 WAS 289 MG | U | 0 | |||||||||
| 127451461 | 12745146 | 4 | SS | LIPOSOMAL DOXORUBICIN | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | OVER 1 HOUR ON DAY 1, LAST DOSE ON 23/AUG/2013 WAS 49 MG | U | 0 | 30 | MG/M**2 | |||||||
| 127451461 | 12745146 | 5 | C | WARFARIN | WARFARIN | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127451461 | 12745146 | 1 | Ovarian epithelial cancer |
| 127451461 | 12745146 | 2 | Ovarian epithelial cancer |
| 127451461 | 12745146 | 3 | Ovarian epithelial cancer |
| 127451461 | 12745146 | 4 | Ovarian epithelial cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127451461 | 12745146 | HO |
| 127451461 | 12745146 | DE |
| 127451461 | 12745146 | OT |
| 127451461 | 12745146 | LT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127451461 | 12745146 | Acidosis | |
| 127451461 | 12745146 | Ascites | |
| 127451461 | 12745146 | Aspiration | |
| 127451461 | 12745146 | Dysphagia | |
| 127451461 | 12745146 | Dyspnoea | |
| 127451461 | 12745146 | Hypertension | |
| 127451461 | 12745146 | Hypoalbuminaemia | |
| 127451461 | 12745146 | International normalised ratio increased | |
| 127451461 | 12745146 | Neutrophil count decreased | |
| 127451461 | 12745146 | Platelet count decreased | |
| 127451461 | 12745146 | Sepsis | |
| 127451461 | 12745146 | Small intestinal obstruction | |
| 127451461 | 12745146 | White blood cell count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127451461 | 12745146 | 1 | 20130823 | 0 | ||
| 127451461 | 12745146 | 2 | 20130823 | 0 | ||
| 127451461 | 12745146 | 3 | 20130823 | 0 | ||
| 127451461 | 12745146 | 4 | 20130823 | 0 |